Trial NCT04649021
Publication Hui A-M, Lancet, 2022
Dates: 2020-12-05 to 2021-01-09
Funding: Private (BioNTech ; Shanghai Fosun Pharmaceutical Development Inc.)
Conflict of interest: Yes
Methods | |
RCT | |
Location :
Multicenter / China Follow-up duration (months): 6 | |
30 mcg BNT162b2 (n = 720) Placebo (n = 240) |
|
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Intervention
2 IM doses of 30 mcg BNT162b2, 21 days apart |
|
Control
2 IM doses of saline placebo, 21 days apart | |
Participants | |
Randomized 960 participants | |
Characteristics of participants Type of participants: Adults N=960 491 males Children: 0 Pregnant women: 0 Immunocompromized patients: 0 Mean age: Age range: 19-84 | |
Description of participants Healthy adults and those with a pre-existing stable condition, at 2 centers in China. | |
Primary outcome | |
In the register 1) SARS-CoV-2 serum neutralizing titers - Seroconversion rates (SCR) [ Time Frame: 1 Month after Dose 2 ] SCR of SARS-CoV-2 serum neutralizing titers at 1-month after dose 2. Seroconversion is defined as ≥4-fold rise from before vaccination to 1-month post dose 2 ; 2) The geometric mean titer (GMT) of SARS-CoV-2 serum neutralizing titers at 1 month after dose 2 [ Time Frame: 1 Month after Dose 2 ] | |
In the report 1) Geometric mean titers (GMTs) against live SARS-CoV-2 and 2) the seroconversion rate (SCR), measured one month after the second dose compared to baseline. | |
Documents available |
Protocol Yes. In English Statistical plan Yes Data-sharing stated:
Yes, Access to data will be made available following
publication upon reasonable
request. |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Low |
General comment | In addition to the pre-print article, the trial registry was used in data extraction and assessment of risk of bias. The supplementary appendices referred to in the article were not available at time of extraction. The primary and secondary outcomes in the article reflect those in the registry. The trial (n = 960) achieved its target sample size (n = 960). The trial was updated on October 27th, 2022 after publication of results at a longer follow-up. |